Key Takeaways Ironwood's Linzess net profit share rose 35% in Q3 to $119.6M on increasing U.S. demand.Strong U.S. demand has driven rising Linzess sales, supporting expectations for continued momentum.Ironwood recorded$244.1M in Linzess net profit share over the first nine months of 2025.Ironwood Pharmaceuticals’ (IRWD) sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent quarters. The company markets Linzess in the United States in collaboration with AbbVie (ABBV) .IRWD an ...